All News
EULAR
OP0041 (2024)
COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
EULAR
OP0092 (2024)
INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
#EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC
Study highlights active signalling pathways assoc with pathotype & drug response
OP0218 @RheumNow https://t.co/RZMSgj9T6k
Mrinalini Dey DrMiniDey ( View Tweet)
Spatial transcriptomics work highlighted at #EULAR2024 @RheumNow https://t.co/5NvX1PW2tA
Links:
Bella Mehta bella_mehta ( View Tweet)
Basic Science highlights at #EULAR2024 @RheumNow https://t.co/gr3Mysp3f4
Bella Mehta bella_mehta ( View Tweet)
New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024
Powerful quote to end @Dr_SBattista’s HPR highlights:
"People working together in a strong community with a shared goal and a common purpose can make the impossible possible"- Tom Vilsack
@RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Interdisciplinary collaboration is the key!
@rheumnow #EULAR2024 https://t.co/pARPUH2ntr
Bella Mehta bella_mehta ( View Tweet)
Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re always struggling.
Telehealth has taught us:
- ideal settings can work, but
- suboptimal inputs inevitably lead to suboptimal results
#EULAR2024 POS0451 @RheumNow https://t.co/fyCQzSl6tB
David Liew drdavidliew ( View Tweet)
placebo effects can be huge!
#EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye
Links:
Bella Mehta bella_mehta ( View Tweet)
Fantastic speakers, chairs and faculty for the #PARE session on self-management.
#EULAR2024 @RheumNow https://t.co/9ulRWL2Mnp
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 highlights
@Dr_SBattista discusses the beneficial effects of exercise for inflammation and general well-being, presented by Prof Kitas
@RheumNow https://t.co/WAHg4ub8R3
Mrinalini Dey DrMiniDey ( View Tweet)
Have RA and want to get pregnant? What can you do?
The answer is simple: disease control.
Implementing T2T in RA led to much better fertility. RA therapy is your friend!
#EULAR2024 POS0436 Rotterdam @RheumNow https://t.co/aoxNakMix1
Links:
David Liew drdavidliew ( View Tweet)
OP0007 (2024)
S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RISK ALLELES, & INADEQUATE RESPONSE TO MTX: RESULTS FROM PH3 AMPLIFIED TRIAL shame seropositivity did not translate to an advantage for AbA @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
PARE summary at #EULAR2024 - love the word cloud highlighting the posters @RheumNow
RA, SLE and JIA were the key RMDs that were focused on. By Silvia Aguleria https://t.co/WbSKwE6vXs
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to severe systemic #Sjogren failed to meet primary endpoint (ESSDAI) or other secondary (ESSPRI, biomarkers). This inhibition unlikely to impact on SjD @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
EULAR PARE highlights
- Need close collaboration between patients and physicians.
-Child to adult transition need to be smooth to be successful (30% patients can be lost in transitions)
- We need patients to participate in Health Technology Assessment
@rheumnow #EULAR2024 https://t.co/50qFpRGXo2
Links:
Bella Mehta bella_mehta ( View Tweet)
Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA!
179 pts
ILD newly developed 9.5%
progressed 12.3%
no change 74.9%
improved 4.5%
5.7% in the LDA group 28.0% non-LDA group (p=0.006)
@RheumNow #EULAR2024 POS0408 https://t.co/7DyXr5zdCM
Aurelie Najm AurelieRheumo ( View Tweet)